06Jun

Before the discovery of antibiotics, tuberculosis was the second most common cause of death in the US. Today, thanks to antibiotics, the few who contract the disease rarely die.

But as TB and other once-easily cured diseases grow increasingly antibiotic resistant, the very real fear is that medicine may run out of treatment options, leading to epidemics dwarfing COVID-19.

To head-off that kind of future, two dozen pharmaceutical firms have invested nearly $1 billion creating the AMR Action Fund with the goal of developing 2-4 new antibiotics by 2030.

AMR – antimicrobial resistance – arises when infectious disease pathogens become resistant to existing medicines. Tuberculosis is one of them, as are several others including the much publicized MRSA.

“AMR has the potential to render diseases that are relatively easy to treat today virtually incurable,” said Dr. Paul Stoffels, vice chairman of the executive committee and chief scientific officer, Johnson & Johnson.

“Left unchecked, AMR could significantly eclipse the global health challenge that the world is facing currently with COVID-19,” he said in a statement announcing the launch of the AMR Action Fund.

The initial funding pledges from the bioscience and drug firms – including $100 million pledged each by Johnson & Johnson and Pfizer – will be supplemented by non-industry partners, the Fund says on its website.

Explaining that “drug resistant bacteria are developing faster than new antibiotics can reach the market,” the Fund says there are few antibiotics in clinical development to meet current and anticipated needs. The reason is that the market for antibiotics “doesn’t support the level of investment needed to maintain a robust antibiotic pipeline.”

The website goes on to explain that smaller biotech firms have trouble financing trials of the antibiotics they do develop. Some that have developed new antibiotics “have declared bankruptcy or exited this space,” cautions the Fund, “Due to the lack of commercial sustainability, resulting in the loss of valuable expertise and resources.”

To achieve its goal of bringing to market the new antibiotics in a decade, the Fund said it “will invest in smaller biotech companies focused on developing new antibiotics that address the highest priority public health needs.”

Specifically, the AMR Action Fund will:

  1. “Invest based on the WHO/CDC priority lists of pathogens, with the goal to address major unmet needs and maximize public health impact.
  2. “Prioritize novel antibacterial treatments, as recognized by leading public health agencies, with significant and differentiated clinical utility and that reduces patient mortality.
  3. “Invest across all stages of clinical development.”

[bdp_post_carousel]

author avatar
Green Key

Green Key Unlocked: Why Green Key?

“We are always inviting new, innovative ideas,” says Brooke Stemen, Director of Talent Acquisition at Green Key. As the person responsible for interviewing and onboarding new recruiters at the agency, Brooke has several reasons why someone should want to work and grow here. If you are looking for a different recruiting experience, or simply trying to switch career paths entirely, Brooke has provided a handful of motivating reasons to consider Green Key Resources. 

1. Commission structure 

The industry standard for commission structures is 5%, but at Green Key, *it typically starts* 12%. As this is more than double, the earning potential is unmatched. We also have zero threshold to earning commission, meaning you will make commission on your very first placement. You will never have to hit a spread quota or achieve a number of placements before unlocking strong earning potential. In addition to a competitive commission structure, Green Key also promotes from within. “We push our management teams to develop their internal teams,” says Brooke. “We are very growth-focused and invested in the success of our recruiters.” With a tech-focused mission and access to industry leading sourcing techniques, employees at Green Key have unlimited opportunities to succeed

2. Flexibility 

Green Key was founded on empathetic leadership, where you are treated like an adult and granted full autonomy to build your own day and optimize your time. Brooke reiterates, “We are not driven by arbitrary numbers, like how many calls you make. We’re a results driven firm and focused on net and production, which is a system that cultivates efficiency.” Green Key is also a give and take environment. Remote and hybrid schedules allow for a trusting relationship and higher productivity. We are always centered on quality of work over quantity. 

3. Mentorship 

Because Green Key promotes from within, managers across the organization are more motivated to mentor their recruiters and facilitate growth. Hierarchies tend to break down in these relationships and promote open communication. Mentorship within various teams is a unique aspect that makes Green Key successful. The opportunity to trust and learn from seasoned recruiters leads to goals being met and a healthy work environment.  

4. Diversity & inclusion 

“Prior to Green Key, I didn’t really see myself represented in leadership,” Brooke mentions. “As a woman who wants children one day, I was thrilled to see so many mothers holding leadership positions here.” Brooke emphasizes that Green Key is a place where you can make a substantial life for yourself, both professionally and personally. If you have to attend to personal matters outside of work, that will never hinder your success or growth here. “All we ask is that when you’re here, be present and try your hardest. At the end of the day, Green Key is an agency made by recruiters for recruiters.” 

Contact us 

If you’re considering a career change, do not hesitate to connect with Brooke on LinkedIn or visit our Join the Green Key Team page. With so many opportunities for growth and advancement, this just might be the perfect place for you! 

author avatar
Green Key
Jun 6, 2023

Study Shows Minorities Underrepresented In Vaccine Trials

Vaccine trials underrepresent large segments of the population, while women are overrepresented, says a study published recently on the JAMA Network Open.

“In this cross-sectional study of 230 US-based clinical trials with 219,555 participants, Black or African American, American Indian or Alaska Native, Hispanic or Latino, and older adults were underrepresented and women were overrepresented compared with the US population,” the research study authors wrote.

Equally significant was the lack of ethnic and racial data reported by trial managers.

“One of the most important findings,” the report says, “Was that despite FDA recommendations, many studies were not complying with reporting guidance regarding demographic characteristics of the study population.”

The researchers found only 34% of the trials reported ethnicity; 58% reported race. All included age and sex data.

“This is a massive gap in information, and if we want to improve enrollment in clinical trials and we want to see diversity in clinical trials, we need the data,” Steven Pergam, an author on the paper told StatNews. “It’s amazing that we don’t have the data.”

Of the trials that did report race, that reported race, Black adults accounted for 11% of the trial participants, 6% were Asian less than one-half of 1% were American Indians, Alaska Natives, Hawaiian or Pacific Islanders.

Whites were 78% of all participants.

In the 79 trials that reported ethnicity, Hispanics and Latinos accounted for 12%.

The imbalance was even more striking in phase 3 trials. There, only 7% of the participants were Black or African American.

“Similarly,” the report says, “Native Hawaiian and Pacific Islander, American Indian and Alaska Native, and Hispanic or Latino participants were underrepresented in phase 3 trials compared with their representation in the US population.”

“Despite advancements, equity in clinical trial enrollment remains an issue,” the report observes.

representation in vaccine trial chart blog.jpg

The underrepresentation of minorities became an issue during the COVID vaccine trials, as pharmaceutical firms struggled to recruit volunteers. Early into the pandemic, a group of US senators wrote to the pharmaceutical companies involved in the Warp Speed vaccine development program saying trials “must include participants that racially, socioeconomically, and otherwise demographically represent the United States.”

It was that difficulty that prompted the writers of the recent paper to study the demographic make-up of vaccine trials over the last decade. Though the differences between the trial participants and the general population were not great, the disparities are enough to be troubling, the researchers said.

“Small inequities are still important inequities,” Laura Flores, lead author on the study told StatNews. “We’re doing a genuine disservice to these populations by not reaching out and not keeping records or not including them in trials that might benefit them.”

Photo by CDC on Unsplash

author avatar
Green Key